The No Pain Act will mandate Medicare insurance coverage for non-opioid pain management, including evidence-based treatments, ...

From family planning to hospital bills, the new Trump administration has the potential to affect a wide range of policies in ...

The Affordable Care Act may not be dismantled, but Americans could see lower subsidies, experts say. Other changes may be in ...

A group of Louisiana health care providers and reproductive rights advocates are challenging the unprecedented action of ...

Avadel CNS Pharmaceuticals, LLC (“Avadel CNS”) intervened to defend the FDA’s actions and successfully argued to uphold approval of LUMRYZ. “We are pleased with the Court’s ruling in favor of the ...

Drug-related supply chain issues in Canada were 40% less likely to result in significant drug shortages than in the United ...

The longtime anti-vaccine activist may be tapped as a White House czar, overseeing agencies responsible for vaccine approvals ...

Avadel Pharmaceuticals (AVDL) announced that yesterday, the U.S. District Court for the District of Columbia ruled in favor of the Food and ...

The Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right To Try Act, aka Right To Try ... We rate ...

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Company has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug ...

On October 4, 2024, a US House version of the revised Promising Pathway Act (PPA) 2.0 was introduced, sponsored by Rep. Bruce Westerman (R-AR).

The US District Court upholds the FDA’s approval of Avadel’s Lumryz, dismissing Jazz’s challenge over market exclusivity for ...